Bio:
Dr. Mellar P. Davis, MD, FCCP FAAHPM, is a member of the Palliative Care Department and Research Director at Geisinger Medical System in Danville, PA. He is a Fellow of the American Academy of Hospice and Palliative Medicine, co-chair of the Pain Study Group of the Palliative Care Study Group of the Multinational Association of Supportive Care (MASCC), and a MASCC board member in 2018 and 2020. He became a Professor of Palliative Medicine at the Geisinger Commonwealth School of Medicine in 2021. He is the recipient of the MASCC Distinguished Service Award and MD Anderson Award for outstanding contributions to the field of cancer pain management in 2023. He has published over 360 peer-reviewed manuscripts and studies, over 100 chapters, and edited eight books.

Learning Objectives
At the conclusion of this activity, the learner should be able to:

• Extrapolate buprenorphine pharmacodynamics into clinical utility.
• Convert from potent opioids to buprenorphine using micro-dosing techniques.
• Select patients who would be appropriate for buprenorphine as a frontline opioid analgesic.